The intervention involves administering ceralasertib, an experimental drug, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily for a week, while the other drugs are administered in single ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Jeff Bernstein, ...

About Parexel Parexel is among the world's largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach ...

The latest international Parexel International Corporation news and views from Reuters - one of the world's largest news agencies ...

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of phase I to IV clinical development services, and Palantir Technologies Inc., a leading builder of ...

Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, have inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug ...

Parexel-Partex collab to use AI-driven solutions to accelerate drug discovery & de-risk biopharmaceutical portfolios. Combining Parexel's clinical dev. expertise & Partex's big data & AI ...

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development.

We’re here today with Jonathan Shough, chief information officer at Parexel, one of the world’s largest clinical research organizations.

Clinical research organization Parexel announced an agreement with MyEyeDr. to refer its eye care patients into clinical trials.

Parexel works with IFS to automate complex processes for productivity and efficiency gains - SiliconANGLEA message from John Furrier, co-founder of SiliconANGLE: Your vote of support is important ...